Table 1.
Treatment | Pharmacological targets | Colocalization ratio |
|
---|---|---|---|
Mean ± SEM | N | ||
Control | 1.01 ± 0.05 | 94 | |
Morphine | μ/δ/κ-opioid R agonist | 1.51 ± 0.04* | 66 |
DAMGO | μ-opioid R agonist | 1.09 ± 0.04 | 20 |
DPDPE | δ-opioid R agonist | 0.94 ± 0.06 | 19 |
Met-enkephalin | μ/δ-opioid R agonist | 1.21 ± 0.06* | 22 |
Bicuculline | GABAAR antagonist | 1.00 ± 0.07 | 10 |
AP5 + CNQX | Ionotropic glutamate R antagonists | 1.00 ± 0.06* | 30 |
GABA | GABAA/BR agonist | 1.12 ± 0.06 | 48 |
Morphine + | |||
Naloxone | μ/δ/κ-opioid R antagonist | 0.80 ± 0.04 | 60 |
Gabazine | GABAAR antagonist | 1.60 ± 0.11* | 42 |
SCH50911 | GABABR antagonist | 1.87 ± 0.10* | 46 |
Gabazine + CGP 35348 | GABAA/GABABR antagonists | 1.67 ± 0.23* | 47 |
AP5 + CNQX | Ionotropic glutamate R antagonists | 1.63 ± 0.06* | 32 |
TTX | Na channel inhibitor | 1.67 ± 0.08* | 46 |
PTX | Gαi/o inhibitor | 1.83 ± 0.08* | 31 |
Neurons were treated with indicated drugs: morphine (100 μm), DAMGO (1 μm), DPDPE (100 μm), met-enkephalin (10 μm), bicuculline (30 μm), GABA (100 μm), naloxone (100 μm), gabazine (10 μm), gabazine (10 μm), CGP 35348 (10 μm), SCH50911 (50 μm), AP5 (100 μm), CNQX (10 μm), TTX (2 μm), and/or PTX (250 ng/ml). PTX was applied during the last 6 h of the morphine treatment. Values shown are the mean colocalization ratio (±SEM). N, Number of dendritic fields analyzed; R, receptor.
*p < 0.05 versus control paired with drugs groups, one-way ANOVA followed by Bonferroni post hoc test for significance.